Breaking News

Lilly Invests $2.5B to Expand Injectable Mfg. Capacity in Germany

Will bolster incretin supply to support increased demand for its diabetes and obesity portfolio.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. plans to build a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany to expand its global parenteral product and device manufacturing network and support increased demand for its diabetes and obesity portfolio.    With the planned manufacturing facility in Alzey, Lilly will operate a total of six manufacturing sites in Europe, including one in nearby Fegersheim, France. Lilly’s ongoing investments in Europe aims to create operational sy...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters